Hamlin Capital Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 710,722 shares of the company’s stock after purchasing an additional 14,598 shares during the period. Johnson & Johnson makes up approximately 4.5% of Hamlin Capital Management LLC’s investment portfolio, making the stock its 7th largest holding. Hamlin Capital Management LLC’s holdings in Johnson & Johnson were worth $125,549,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Lincoln Capital Corp increased its holdings in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after purchasing an additional 183 shares during the period. Ieq Capital LLC grew its holdings in Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after acquiring an additional 6,154 shares during the period. RFG Advisory LLC grew its holdings in Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after acquiring an additional 594 shares during the period. Willis Investment Counsel grew its holdings in Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after acquiring an additional 1,358 shares during the period. Finally, FDx Advisors Inc. grew its holdings in Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after acquiring an additional 153 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.35% of the company’s stock.
Johnson & Johnson Trading Up 1.0 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same period last year, the business earned $2.13 EPS. The business’s quarterly revenue was down 4.4% on a year-over-year basis. As a group, analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of research analyst reports. UBS Group initiated coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Piper Sandler lowered their target price on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Citigroup increased their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Finally, StockNews.com initiated coverage on Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $173.67.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
